Prime Medicine, Inc. (NYSE:PRME – Get Free Report) has earned an average rating of “Moderate Buy” from the ten research firms that are presently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and nine have issued a buy recommendation on the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $14.11.
A number of research firms have recently commented on PRME. StockNews.com upgraded Prime Medicine to a “sell” rating in a research note on Wednesday, August 7th. HC Wainwright reiterated a “buy” rating and issued a $10.00 target price on shares of Prime Medicine in a research note on Wednesday. Finally, Wedbush restated an “outperform” rating and set a $12.00 price target on shares of Prime Medicine in a research note on Thursday, August 8th.
Read Our Latest Research Report on Prime Medicine
Institutional Inflows and Outflows
Prime Medicine Price Performance
PRME opened at $3.41 on Friday. The firm’s fifty day moving average price is $4.19 and its two-hundred day moving average price is $5.43. The company has a market capitalization of $409.30 million, a price-to-earnings ratio of -1.57 and a beta of 2.18. Prime Medicine has a 1 year low of $3.28 and a 1 year high of $9.86.
Prime Medicine (NYSE:PRME – Get Free Report) last posted its earnings results on Thursday, August 8th. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.40) by ($0.06). As a group, equities analysts anticipate that Prime Medicine will post -1.76 EPS for the current year.
Prime Medicine Company Profile
Prime Medicine, Inc, a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence.
Further Reading
- Five stocks we like better than Prime Medicine
- Buy P&G Now, Before It Sets A New All-Time High
- When Is the Best Time to Invest in Mutual Funds?
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- Is NVIDIA Stock in a Correction or Consolidation?
- Retail Stocks Investing, Explained
- 3 Oversold Stocks with Big RSI Rebound Potential
Receive News & Ratings for Prime Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prime Medicine and related companies with MarketBeat.com's FREE daily email newsletter.